Transcutaneous vaccines-current and emerging strategies

Expert Opinion on Drug Delivery

Volumn 10, Issue 4, 2013, Pages 485-498

  Hirobe, Sachiko ^a   Okada, Naoki ^a   Nakagawa, Shinsaku ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Adjuvant; Clinical study; Microneedle; Skin; Transcutaneous vaccination

Indexed keywords

ALUMINUM HYDROXIDE; BOVINE SERUM ALBUMIN; CALCEIN; CHITOSAN; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; DIPHTHERIA TOXOID; DNA VACCINE; DODECYL SULFATE SODIUM; DRUG CARRIER; ERYTHROPOIETIN; ESCHERICHIA COLI ENTEROTOXIN; ETHOSOME; FREUND ADJUVANT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HYALURONIC ACID; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INSULIN; LIPOSOME; NANOPARTICLE; NIOSOME; OVALBUMIN; POLYGLACTIN; POLYLACTIC ACID; TETANUS TOXOID; TOLL LIKE RECEPTOR; TRANSFERSOMES; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ELECTROPORATION; HUMAN; HYDROGEL; IMMUNE RESPONSE; JET INJECTOR; MATERIAL COATING; MICRONEEDLE; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SKIN PENETRATION; TRANSCUTANEOUS VACCINATION; TRANSDERMAL PATCH; ULTRASOUND; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIGENS; CHEMISTRY, PHARMACEUTICAL; DEVELOPING COUNTRIES; ELECTROPORATION; HUMANS; IMMUNIZATION; NANOPARTICLES; SKIN; TECHNOLOGY, PHARMACEUTICAL; TRANSDERMAL PATCH; VACCINATION; VACCINES;

EID: 84875146150     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.760542     Document Type: Review

References (127)

1. Leppin A, Aro AR. Risk perceptions related to SARS and avian influenza: Theoretical foundations of current empirical research. Int J Behav Med 2009;16:7-29
2. Haque A, Lucas B, Hober D. Influenza A/H5N1 virus outbreaks and prepardness to avert flu pandemic. Ann Biol Clin (Paris) 2007;65:125-33
3. Valadas E, Antunes F. Tuberculosis, a re-emergent disease. Eur J Radiol 2005;55:154-7
4. Campbell CC. Malaria: An emerging and re-emerging global plague. FEMS Immunol Med Microbiol 1997;18:325-31
5. Jones JH, Salathe M. Early assessment of anxiety and behavioral response to novel swine-origin influenza A(H1N1). PLoS One 2009;4:e8032
6. Azad N, Rojanasakul Y. Vaccine delivery-current trends and future. Curr Drug Deliv 2006;3:137-46
7. Kersten G, Hirschberg H. Needle-free vaccine delivery. Expert Opin Drug Deliv 2007;4:459-74
8. UNICEF's work on immunisation. Available from: Http://www.unicef.org. uk/UNICEFs-Work/What-we-do/UNICEFs-work-on-immunisation/
9. Glenn GM, Scharton-Kersten T, Alving CR. Advances in vaccine delivery: Transcutaneous immunisation. Expert Opin Investig Drugs 1999;8:797-805
10. Levine MM. Can needle-free administration of vaccines become the norm in global immunization? Nat Med 2003;9:99-103
11. Mathers AR, Larregina AT. Professional antigen-presenting cells of the skin. Immunol Res 2006;36:127-36
12. Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system. Immunobiology 2008;213:251-60
13. Sugita K, Kabashima K, Atarashi K, et al. Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin. Clin Exp Immunol 2007;147:176-83
14. Mutyambizi K, Berger CL, Edelson RL. The balance between immunity and tolerance: The role of Langerhans cells. Cell Mol Life Sci 2009;66:831-40
15. Nestle FO, Nickoloff BJ. Deepening our understanding of immune sentinels in the skin. J Clin Invest 2007;117:2382-5
16. Valladeau J, Saeland S. Cutaneous dendritic cells. Semin Immunol 2005;17:273-83
17. Gockel CM, Bao S, Beagley KW. Transcutaneous immunization induces mucosal and systemic immunity: A potent method for targeting immunity to the female reproductive tract. Mol Immunol 2000;37:537-44
18. Rougier A, Rallis M, Krien P, et al. In vivo percutaneous absorption: A key role for stratum corneum/vehicle partitioning. Arch Dermatol Res 1990;282:498-505
19. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000;9:165-9
20. Barry BW. Breaching the skin's barrier to drugs. Nat Biotechnol 2004;22:165-7
21. Glenn GM, Villar CP, Flyer DC, et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: Use of skin pretreatment to disrupt the stratum corneum. Infect Immun 2007;75:2163-70
22. McKenzie R, Bourgeois AL, Frech SA, et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007;25:3684-91
23. Glenn GM, Taylor DN, Li X, et al. Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nat Med 2000;6:1403-6
24. Frech SA, Dupont HL, Bourgeois AL, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: A phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008;371:2019-25
25. Frech SA, Kenney RT, Spyr CA, et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005;23:946-50
26. Yagi H, Hashizume H, Horibe T, et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 2006;66:10136-44
27. Vogt A, Mahe B, Costagliola D, et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunol 2008;180:1482-9
28. Combadiere B, Vogt A, Mahe B, et al. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: A randomized phase I trial. PLoS One 2010;5:e10818
29. Ishii Y, Nakae T, Sakamoto F, et al. A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. J Control Release 2008;131:113-20
30. Matsuo K, Ishii Y, Quan YS, et al. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. J Control Release 2011;149:15-20
31. Matsuo K, Ishii Y, Quan YS, et al. Compositional optimization and safety assessment of a hydrogel patch as a transcutaneous immunization device. Biol Pharm Bull 2011;34:1835-40
32. Matsuo K, Ishii Y, Quan YS, et al. Characterization of transcutaneous protein delivery by a hydrogel patch in animal, human, and tissue-engineered skin models. Biol Pharm Bull 2011;34:586-9
33. Hirobe S, Matsuo K, Quan YS, et al. Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria. Vaccine 2012;30:1847-54
34. Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: Effect of particle size and charge. Int J Pharm 2004;275:13-17
35. Shaker DS, Sloat BR, Le UM, et al. Immunization by application of DNA vaccine onto a skin area wherein the hair follicles have been induced into anagen-onset stage. Mol Ther 2007;15:2037-43
36. Vogt A, Combadiere B, Hadam S, et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 2006;126:1316-22
37. Schlosser E, Mueller M, Fischer S, et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008;26:1626-37
38. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55:329-47
39. Mattheolabakis G, Lagoumintzis G, Panagi Z, et al. Transcutaneous delivery of a nanoencapsulated antigen: Induction of immune responses. Int J Pharm 2010;385:187-93
40. Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: A promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 2010;58:1423-30
41. Prego C, Paolicelli P, Diaz B, et al. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 2010;28:2607-14
42. Bal SM, Slutter B, Jiskoot W, et al. Small is beautiful: N-trimethyl chitosanovalbumin conjugates for microneedle-based transcutaneous immunisation. Vaccine 2011;29:4025-32
43. Bal SM, Slutter B, van Riet E, et al. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J Control Release 2010;142:374-83
44. Bal SM, Ding Z, Kersten GF, et al. Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm Res 2010;27:1837-47
45. El Maghraby GM, Williams AC, Barry BW. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm 2004;276:143-61
46. Paul A, Cevc G, Bachhawat BK. Transdermal immunization with large proteins by means of ultradeformable drug carriers. Eur J Immunol 1995;25:3521-4
47. Paul A, Cevc G, Bachhawat BK. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine 1998;16:188-95
48. Gupta PN, Mishra V, Rawat A, et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: A comparative study. Int J Pharm 2005;293:73-82
49. Mishra D, Mishra PK, Dubey V, et al. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur J Pharm Sci 2008;33:424-33
50. Jain S, Vyas SP. Mannosylated niosomes as carrier adjuvant system for topical immunization. J Pharm Pharmacol 2005;57:1177-84
51. Dahlan A, Alpar HO, Stickings P, et al. Transcutaneous immunisation assisted by low-frequency ultrasound. Int J Pharm 2009;368:123-8
52. Tezel A, Paliwal S, Shen Z, et al. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 2005;23:3800-7
53. Dahlan A, Alpar HO, Murdan S. An investigation into the combination of low frequency ultrasound and liposomes on skin permeability. Int J Pharm 2009;379:139-42
54. Weaver JC. Electroporation theory. Concepts and mechanisms. Methods Mol Biol 1995;55:3-28
55. Prausnitz MR, Bose VG, Langer R, et al. Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 1993;90:10504-8
56. Vanbever R, Lecouturier N, Preat V. Transdermal delivery of metoprolol by electroporation. Pharm Res 1994;11:1657-62
57. Zhao YL, Murthy SN, Manjili MH, et al. Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization. Vaccine 2006;24:1282-90
58. Cristillo AD, Weiss D, Hudacik L, et al. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun 2008;366:29-35
59. Hirao LA, Wu L, Khan AS, et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008;26:440-8
60. Macklin MD, McCabe D, McGregor MW, et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 1998;72:1491-6
61. Chen D, Zuleger C, Chu Q, et al. Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. AIDS Res Hum Retroviruses 2002;18:715-22
62. Kelly K, Loskutov A, Zehrung D, et al. Preventing contamination between injections with multiple-use nozzle needle-free injectors: A safety trial. Vaccine 2008;26:1344-52
63. Chen D, Weis KF, Chu Q, et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J Virol 2001;75:11630-40
64. Chen D, Endres R, Maa YF, et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 2003;21:2830-6
65. Roberts LK, Barr LJ, Fuller DH, et al. Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine 2005;23:4867-78
66. Drape RJ, Macklin MD, Barr LJ, et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006;24:4475-81
67. Dincer Z, Jones S, Haworth R. Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. Exp Toxicol Pathol 2006;57:351-7
68. Cassaday RD, Sondel PM, King DM, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 2007;13:540-9
69. Braun RP, Dong L, Jerome S, et al. Multi-antigenic DNA immunization using herpes simplex virus type 2 genomic fragments. Hum Vaccin 2008;4:36-43
70. Jones S, Evans K, McElwaine-Johnn H, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009;27:2506-12
71. Wang R, Epstein J, Baraceros FM, et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 2001;98:10817-22
72. Epstein JE, Gorak EJ, Charoenvit Y, et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002;13:1551-60
73. Williams J, Fox-Leyva L, Christensen C, et al. Hepatitis A vaccine administration: Comparison between jet-injector and needle injection. Vaccine 2000;18:1939-43
74. Aboud S, Nilsson C, Karlen K, et al. Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin Vaccine Immunol 2010;17:1124-31
75. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2286-94
76. Kenney RT, Frech SA, Muenz LR, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004;351:2295-301
77. BD SoulviaTM Prefillable Microinjection System. Available from: Http://www.bd. com/pharmaceuticals/products/microinjection.asp 78.
78. Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007;25:8833-42
79. Prymula R, Usluer G, Altinel S, et al. Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey. Adv Ther 2012;29:41-52
80. Gerstel MS, Place VA. Drug delivery device. US Patent No. 3 1976;964:482
81. Reihsner R, Balogh B, Menzel EJ. Two-dimensional elastic properties of human skin in terms of an incremental model at the in vivo configuration. Med Eng Phys 1995;17:304-13
82. Widera G, Johnson J, Kim L, et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006;24:1653-64
83. Martanto W, Moore JS, Kashlan O, et al. Microinfusion using hollow microneedles. Pharm Res 2006;23:104-13
84. Martanto W, Moore JS, Couse T, et al. Mechanism of fluid infusion during microneedle insertion and retraction. J Control Release 2006;112:357-61
85. Davis SP, Landis BJ, Adams ZH, et al. Insertion of microneedles into skin: Measurement and prediction of insertion force and needle fracture force. J Biomech 2004;37:1155-63
86. Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. Drug Deliv 2010;17:187-207
87. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008;26:1261-8
88. Prausnitz MR, Mikszta JA, Cormier M, et al. Microneedle-based vaccines. Curr Top Microbiol Immunol 2009;333:369-93
89. Henry S, McAllister DV, Allen MG, et al. Microfabricated microneedles: A novel approach to transdermal drug delivery. J Pharm Sci 1998;87:922-5
90. Banks SL, Pinninti RR, Gill HS, et al. Flux across [corrected] microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharm Res 2008;25:1677-85
91. Verbaan FJ, Bal SM, van den Berg DJ, et al. Improved piercing of microneedle arrays in dermatomed human skin by an impact insertion method. J Control Release 2008;128:80-8
92. Ding Z, Verbaan FJ, Bivas-Benita M, et al. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Control Release 2009;136:71-8
93. Ding Z, Van Riet E, Romeijn S, et al. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharm Res 2009;26:1635-43
94. Mikszta JA, Alarcon JB, Brittingham JM, et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002;8:415-19
95. McAllister DV, Wang PM, Davis SP, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. Proc Natl Acad Sci USA 2003;100:13755-60
96. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009;27:454-9
97. Matriano JA, Cormier M, Johnson J, et al. Macroflux microprojection array patch technology: A new and efficient approach for intracutaneous immunization. Pharm Res 2002;19:63-70
98. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release 2007;117:227-37
99. Zhu Q, Zarnitsyn VG, Ye L, et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci USA 2009;106:7968-73
100. Chen X, Prow TW, Crichton ML, et al. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release 2009;139:212-20
101. Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharm Res 2007;24:1369-80
102. Kim YC, Quan FS, Compans RW, et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release 2010;142:187-95
103. Kim YC, Quan FS, Compans RW, et al. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res 2011;28:135-44
104. Hooper JW, Golden JW, Ferro AM, et al. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 2007;25:1814-23
105. Miyano T, Tobinaga Y, Kanno T, et al. Sugar micro needles as transdermic drug delivery system. Biomed Microdevices 2005;7:185-8
106. Ito Y, Hagiwara E, Saeki A, et al. Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci 2006;29:82-8
107. Ito Y, Yoshimitsu J, Shiroyama K, et al. Self-dissolving microneedles for the percutaneous absorption of EPO in mice. J Drug Target 2006;14:255-61
108. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010;16:915-20
109. Matsuo K, Yokota Y, Zhai Y, et al. A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. J Control Release 2012;161:10-17
110. Matsuo K, Hirobe S, Yokota Y, et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J Control Release 2012;160:495-501
111. Glenn GM, Rao M, Matyas GR, et al. Skin immunization made possible by cholera toxin. Nature 1998;391:851
112. Tierney R, Beignon AS, Rappuoli R, et al. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J Infect Dis 2003;188:753-8
113. Beignon AS, Briand JP, Muller S, et al. Immunization onto bare skin with synthetic peptides: Immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 2002;105:204-12
114. Ozaki T, Yauchi M, Xin KQ, et al. Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant. Viral Immunol 2005;18:373-80
115. Kahlon R, Hu Y, Orteu CH, et al. Optimization of epicutaneous immunization for the induction of CTL. Vaccine 2003;21:2890-9
116. Anjuere F, George-Chandy A, Audant F, et al. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J Immunol 2003;170:1586-92
117. Medzhitov R, Preston-Hurlburt P, Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7
118. Manning BM, Enioutina EY, Visic DM, et al. CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp Gerontol 2001;37:107-26
119. Seya T, Akazawa T, Tsujita T, et al. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based Complement Alternat Med 2006;3:31-8.discussion 133-137
120. Thissen MR, Kuijpers DI, Krekels GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: A report of 3 cases. J Drugs Dermatol 2006;5:461-4
121. Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine 2006;24:1958-65
122. Zhu J, Lai K, Brownile R, et al. Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod. Mol Immunol 2008;45:3238-43
123. Combadiere B, Liard C. Transcutaneous and intradermal vaccination. Hum Vaccin 2011;7:811-27
124. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012;64:1547-68
125. van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 2012;161:645-55
126. Celli S, Albert ML, Bousso P. Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy. Nat Med 2011;17:744-9
127. Ouchi T, Kubo A, Yokouchi M, et al. Langerhans cell antigen capture through tight junctions confers preemptive immunity in experimental staphylococcal scalded skin syndrome. J Exp Med 2011;208:2607-13